Breaking News, Collaborations & Alliances

Alloy Therapeutics Partners with Takeda on iPSC-Derived Cell Therapies

Will focus on accelerating the development of key therapies to overcome solid and hematological malignancies.

Author Image

By: Charlie Sternberg

Associate Editor

Alloy Therapeutics, a biotechnology company focused on drug discovery, has entered into a strategic collaboration and license agreement with Takeda Pharmaceutical to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK).   “This agreement between Takeda and Alloy aims to advance iCAR-T from discovery to clinical development,” said Yasushi Kajii, Head of R&D Japan Region at Takeda. “We look forward t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters